ReviewMetabolic brain disease2025
The beneficial effects of D-allose and D-allulose on the brain under ischemic stroke and obese-insulin resistant conditions: evidence from in vitro to clinical studies.
Review in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ischemic stroke, and obese-insulin resistance are common pathological conditions that lead to brain injury, resulting in neurodegeneration, brain atrophy, and cognitive dysfunction. Rare sugars, which are scarce monosaccharide in nature, have been investigated as a potential treatment for these adverse conditions. However, the beneficial effects of rare sugars on the brain have never been summarized. Therefore, this article comprehensively summarizes and discusses the benefits of rare sugars on the brain under physiological condition, ischemic stroke, and obese-insulin resistance. The potential mechanisms mediating these benefits of rare sugars are also described. Any contradictory findings are also included. This article adds weight to the impetus for further investigations into the applications of rare sugars as a novel therapeutic paradigm in clinical application.
Indexed as
Identifiers
40153100What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.